DDInter1266 DDInter1492
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Ponatinib
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Naproxen {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
TXLNA {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Ponatinib
Naproxen {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Naproxen (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) is downregulated by Ponatinib (Compound)
Naproxen (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Naproxen (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Ponatinib
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Ponatinib
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Naproxen (Compound) downregulates TXLNA (Gene) and TXLNA (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Ponatinib (Compound)
Naproxen (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Naproxen (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib